Favrille Cleared to Begin Clinical Testing of Lymphoma Drug
Posted on: Friday, 16 June 2006, 12:00 CDT
Biopharmaceutical company Favrille has received the go-ahead from the FDA to begin human testing of its FAV-201 immunotherapy for the treatment of T-cell lymphoma.
Favrille now intends to initiate a phase I/II clinical trial evaluating the safety and biologic activity of FAV-201 in patients with cutaneous T-cell lymphoma.
The trial will build upon preclinical data that suggest activity of an immunotherapy based on a T-cell receptor. The multi-center trial is expected to enroll approximately 30 patients.
"This new product candidate represents an extension of our platform and draws on our success to date in the development of our lead product candidate FavId for the treatment of B-cell non-Hodgkin's lymphoma (NHL)," said Dr John Longenecker, president and CEO of Favrille.
FAV-201 is a recombinant, patient-specific, T-cell receptor-based immunotherapy designed to induce an active immune response against the unique protein found on the surface of T-cells that constitute a patient's lymphoma. Favrille uses a similar approach with its lead product candidate FavId for the treatment of B-cell NHL.
In January the company completed enrollment in a pivotal phase III clinical trial of FavId following induction therapy with Rituxan, the current standard of care. Favrille has received fast track designation from the FDA for FavId.
Source: Datamonitor
Related Articles
- Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma
- Cell Genesys Announces Termination of VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer Based on Outcome of Futility Analysis and Reports Preliminary Analysis of VITAL-2 Trial Results
- Cell Genesys Reports Updated Results From Phase 1 Clinical Trial of GVAX Immunotherapy for Prostate Cancer Used in Combination With Ipilimumab
- Cell Genesys Completes Patient Recruitment for First Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
- Favrille Announces Data From Phase 2 Clinical Trial of FavId for Indolent B-Cell Non-Hodgkin's Lymphoma in Europe
- Cell Genesys Reports Long-Term Follow-Up Data From Phase 2 Trial of GVAX(R) Immunotherapy For Leukemia in Chronic Myelogenous Leukemia
- Cell Genesys Reports Encouraging Follow-Up Survival Data From Second Phase 2 Trial of GVAX(R) Immunotherapy for Prostate Cancer
- Favrille Completes Patient Enrollment in Pivotal Phase 3 Clinical Trial of FavId for Follicular B-Cell Non-Hodgkin's Lymphoma
- Phase II Study Demonstrates That ONTAK(R) Benefits Patients With Relapsed/Refractory T-Cell Non-Hodgkin's Lymphoma
- Abstracts Demonstrate That ONTAK May Benefit Patients With Relapsed/Refractory T-Cell Non-Hodgkin's Lymphoma and B-Cell Chronic Lymphocytic Leukemia
 |
 |
User Comments (0)
RSS Feeds